New Zealand markets closed

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.1000+0.0400 (+3.77%)
At close: 04:00PM EDT
1.1500 +0.05 (+4.55%)
After hours: 07:50PM EDT

Aridis Pharmaceuticals, Inc.

983 University Avenue
Building B
Los Gatos, CA 95032
United States
408 385 1742
https://www.aridispharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees34

Key executives

NameTitlePayExercisedYear born
Dr. Vu L. Truong Ph.D.Founder, CEO, Chief Scientific Officer & Director576.25kN/A1964
Mr. Fred Kurland J.D., M.B.A.Chief Financial Officer305.89kN/A1951
Dr. Hasan Jafri M.D.Chief Medical Officer537.2kN/AN/A
Mr. Jeffrey J. Fessler Esq., J.D.Acting Gen. CounselN/AN/A1963
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Corporate governance

Aridis Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.